New-Onset Methamphetamine Heart Failure Looks the Same on Echocardiography

Methamphetamine-associated heart failure has long been suspected of carrying a telltale signature on ultrasound images of the heart, a pattern that clinicians hoped could speed diagnosis in emergency settings. A new retrospective cohort study now reports that, at the moment of first diagnosis, that signature may not exist. Researchers comparing patients hospitalized with new-onset heart failure related to methamphetamine use against carefully matched controls found no significant differences across a full panel of echocardiographic measures, from pumping function to chamber sizes to pressures in the lungs.

The study, published in Echo Research & Practice, enrolled 75 patients with methamphetamine-associated heart failure, identified through positive urine drug screens, diagnostic codes for incident heart failure, and clinical documentation confirming active methamphetamine use within the week before their index hospitalization. Each case was matched one-to-one with a control patient who had acute heart failure from non-ischemic cardiomyopathy unrelated to methamphetamine, with no history of the drug and a negative drug screen. Matching was performed on age within two years, sex, and race, producing a comparison group of 75 controls and a total analytic cohort of 150 patients.

The investigators deliberately focused on the initial transthoracic echocardiogram performed during each patient’s first hospitalization for heart failure. This timing matters, they argue, because nearly all previous imaging studies of methamphetamine-associated heart failure examined patients with established, chronic disease, leaving the phenotype at the moment of diagnosis largely undefined. Their pre-specified endpoints included left and right ventricular size and function, left ventricular thrombi, valvular dysfunction, and pulmonary artery systolic pressure.

The central result was uniformly negative. Left ventricular ejection fraction, a measure of pumping capacity, averaged 28 percent in the methamphetamine group versus 25 percent in controls, both indicating severely reduced systolic function, and the difference was not statistically significant. Left ventricular end-diastolic volume indexed to body surface area, a marker of chamber enlargement, measured 103 milliliters per square meter in cases against 94 milliliters per square meter in controls, again without a significant gap. Left atrial size, right ventricular size and function, the presence of ventricular thrombi, and pulmonary artery pressures were all similar between the groups.

Diastolic function, the heart’s relaxation and filling behavior, proved harder to assess. Imaging quality problems, uninterpretable findings in the setting of atrial fibrillation, or internally contradictory parameters left usable diastolic data for only 54 patients, 29 cases and 25 controls, a missing rate of 64 percent. Within that reduced sample, the researchers identified no significant differences in diastolic function. Because many statistical comparisons were performed, the team applied a Bonferroni correction, a conservative adjustment that raises the bar for declaring a difference real.

The two cohorts did differ in ways that extended beyond the heart images. Patients with methamphetamine-associated heart failure had lower body mass index, higher rates of public insurance, and higher rates of housing instability than controls. They also carried higher rates of comorbid substance use disorders, schizophrenia, and psychosis. The authors note that housing instability, public insurance, and psychiatric comorbidity are well-described features of populations who use methamphetamine generally, not quirks of this particular cohort, but they acknowledge that these social drivers of health may have influenced access to care, continuity of follow-up, or the timing of clinical presentation in ways this cross-sectional comparison could not capture.

The negative findings stand in sharp contrast to earlier studies of chronic methamphetamine-associated heart failure, which reported larger left atria, larger left ventricular end-diastolic volumes, lower ejection fractions, more severe right ventricular dysfunction, and a higher prevalence of left ventricular thrombi compared with patients whose heart failure had other causes. The authors speculate that their cohort captured an earlier stage of disease, with possibly shorter duration of methamphetamine exposure, less myocardial fibrosis, and less ventricular remodeling. They are careful to flag this explanation as speculative: the study did not collect data on the duration, frequency, or cumulative dose of methamphetamine use, so any exposure-based interpretation requires prospective validation with detailed exposure histories.

Methamphetamine is known to drive dilated cardiomyopathy through several mechanisms, including excess sympathetic nervous system activation, direct toxicity to heart muscle cells, and eventual myocardial fibrosis. Hospitalizations for methamphetamine-associated heart failure rose between 2008 and 2020, creating a substantial healthcare burden. The stakes of early detection are illustrated by prior work showing that methamphetamine cessation is associated with less myocardial fibrosis and improvement in left ventricular ejection fraction, while continued use leads to progressive decline in systolic function. Early diagnosis also opens the door to timely initiation of guideline-directed medical therapy, which can yield clinical improvement in this population.

The clinical implication the authors draw is diagnostic humility. If methamphetamine-associated heart failure cannot be distinguished by imaging from other forms of heart failure, clinicians evaluating a patient with new-onset heart failure and suspected methamphetamine involvement should rely on clinical history and urine drug screening rather than specific echocardiographic features. Just as importantly, they argue, patients who use methamphetamine and develop heart failure warrant a thorough work-up to exclude other reversible causes of cardiomyopathy, since methamphetamine-associated heart failure is a diagnosis of exclusion and prior work suggests these patients often do not receive a comprehensive evaluation for alternative etiologies.

The study’s limitations frame how far its conclusions can travel. It was a single-center, retrospective analysis, which limits generalizability, and the sample of 75 cases may have been too small to detect subtle differences in echocardiographic parameters. The high proportion of patients with incomplete diastolic data further constrained that analysis, and the study was underpowered for subgroup analyses based on the demographic differences between groups, such as housing instability, psychiatric diagnoses, or body mass index. Although the authors speculated that patients had earlier-stage disease because this was their first heart failure hospitalization, they lacked the data to statistically assess differences in symptom severity classes between cases and controls. Substance use was established through urine drug screens and patient history, the latter subject to suspected underreporting, and no information on exposure duration, frequency, or dose was recorded. As an initial analysis, the dataset also included no follow-up imaging or clinical outcomes.

Looking forward, the authors propose that future echocardiographic research should test global longitudinal strain, an advanced ultrasound measure of myocardial deformation that can detect subclinical dysfunction before conventional parameters deteriorate. Strain analysis is already widely used in cardio-oncology and transplant cardiology to monitor patients for early heart muscle injury, and the authors suggest it could be applied similarly to methamphetamine and other toxin-associated cardiomyopathies. If strain proves sensitive to early changes that standard measures miss, it could eventually restore the hope that motivated this study: an imaging tool that identifies methamphetamine-related heart damage early enough for cessation support and guideline-directed therapy to intervene before fibrosis and remodeling take hold. For now, however, the message from this cohort is that a first hospitalization echocardiogram alone cannot tell the story, and the diagnosis must be built from the full clinical picture.

Subject of Research: Echocardiographic findings at initial diagnosis of methamphetamine-associated heart failure compared with matched non-ischemic cardiomyopathy controls

Article Title: Echocardiographic characteristics of new-onset methamphetamine-associated heart failure: a retrospective cohort study

Article References: Chiang, J., Hidano, D., Herren, H., Longenecker, C. T., Yadava, M., & Kersey, C. B. (2026). Echocardiographic characteristics of new-onset methamphetamine-associated heart failure: a retrospective cohort study. Echo Research & Practice, 13(1), Article 31. https://doi.org/10.1186/s44156-026-00133-3

Image Credits: AI Generated

DOI: 10.1186/s44156-026-00133-3

Keywords: methamphetamine-associated heart failure, echocardiography, non-ischemic cardiomyopathy, retrospective cohort study, left ventricular ejection fraction, diastolic function, heart failure diagnosis, myocardial fibrosis, guideline-directed medical therapy, global longitudinal strain, diagnosis of exclusion, ventricular remodeling